Investigational drug · Phase 2
RBP-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Uveal Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RBP-01"
First trial start
2026
Oct 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBP-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uveal Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "RBP-01" as an intervention, largest first.
- Study of Neoadjuvant RBP-01 In Patients With Primary Uveal MelanomaNot yet recruiting
ReBio PharmaIndustry
NCT07747935 · 30 participants (planned) · Start Oct 1, 2026 · Primary completion Apr 1, 2028
Drug: RBP-01 · For: Uveal Melanoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Uveal Melanoma
- DarovasertibIDE 196, LXS196Phase 35 trials
IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma
- AU-011Bel-sarPhase 32 trials
Aura Biosciences · Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma
- APG-115Phase 24 trials
Ascentage Pharma Group Inc. · T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma, Liposarcoma
- roginolisibIOA-244Phase 23 trials
iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.